NCT03422666View on ClinicalTrials.gov

Plasma Lipoprotein Response to Glucagon-like Peptide-2

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

June 1, 2021

Study Completion Date

December 1, 2021

Conditions
Hyperlipidemias
Interventions
DRUG

Teduglutide

Teduglutide

DRUG

Placebo

Placebo

Trial Locations (1)

M5G 2C4

Toronto General Hopital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03422666 - Plasma Lipoprotein Response to Glucagon-like Peptide-2 | Biotech Hunter | Biotech Hunter